Tizanidne Hydrochloride Capsule
Product Images NDC 71335-2210

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidne Hydrochloride (NDC 71335-2210). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713352210)

Label of Tizanidine Hydrochloride Capsules 6 mg with 150 capsules per container. The label indicates the product is relabeled by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Alkem Laboratories Ltd. It includes storage instructions and a note that the capsules are not interchangeable with tizanidine tablets or Zanaflex tablets. The label displays the NDC 71335-2210-1 and barcodes.*

FDA Label Image

Tiz01 (Tiz01)

Chemical structure diagram of Tizanidine Hydrochloride showing its molecular framework including a chlorinated benzene ring fused with a thiazole and an imidazoline ring, along with the hydrochloride (HCl) component.*

FDA Label Image

Tiz02 (Tiz02)

A line graph showing plasma Tizanidine concentration (ng/mL) over time (hours) from dosing. It compares four dosing conditions: 2 x 4 mg Tizanidine tablets with food, 2 x 4 mg tablets without food, 2 x 4 mg capsules with food, and 2 x 4 mg capsules without food. Concentrations peak around 1-2 hours and decline to near zero by 16 hours.*

FDA Label Image

Tiz03 (Tiz03)

A line graph showing improvement in Ashworth Score over 6 hours post-dose for 16 mg tizanidine, 8 mg tizanidine, and placebo. The vertical axis represents improvement in Ashworth Score, and the horizontal axis shows hours post-dose. Data points include error bars indicating variability for each treatment group.*

FDA Label Image

Tiz04 (Tiz04)

A line graph depicting improvement in Ashworth Score over three time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carried Forward). The graph compares two groups: tizanidine (mean dose 28.8 mg), which shows negative score improvements indicating better outcomes, and placebo, which shows minimal improvement with scores near zero. Error bars represent variability in the measurements.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.